These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27746884)

  • 1. Erlotinib Induced Fatal Interstitial Lung Disease in a Patient with Metastatic Non-Small Cell Lung Cancer: Case Report and Review of Literature.
    Mangla A; Agarwal N; Carmel C; Lad T
    Rare Tumors; 2016 Sep; 8(3):6410. PubMed ID: 27746884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.
    Makris D; Scherpereel A; Copin MC; Colin G; Brun L; Lafitte JJ; Marquette CH
    BMC Cancer; 2007 Aug; 7():150. PubMed ID: 17683587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erlotinib-associated near-fatal interstitial pneumonitis in a patient with relapsed lung adenocarcinoma.
    Chou CL; Ko HW; Wang CW; Yu CT; Kuo HP; Huang CD
    Chang Gung Med J; 2010; 33(1):100-5. PubMed ID: 20184801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatal interstitial lung disease after erlotinib for non-small cell lung cancer.
    Lind JS; Smit EF; Grünberg K; Senan S; Lagerwaard FJ
    J Thorac Oncol; 2008 Sep; 3(9):1050-3. PubMed ID: 18758310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review.
    Lai YC; Lin PC; Lai JI; Hsu SY; Kuo LC; Chang SC; Wang WS
    Int J Clin Pharmacol Ther; 2011 Jul; 49(7):461-6. PubMed ID: 21726497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose corticosteroid therapy for erlotinib-induced interstitial lung disease in Japanese patient with advanced pancreatic cancer.
    Yoshioka M; Watanabe G; Uchinami H; Ise N; Nakagawa Y; Kudoh K; Morita R; Andoh H; Yamamoto Y
    JOP; 2014 Nov; 15(6):611-4. PubMed ID: 25435581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases.
    Arakawa N; Tsujita A; Saito N; Ishikawa S; Ohno S
    Respirol Case Rep; 2013 Sep; 1(1):17-9. PubMed ID: 25473530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
    Yoneda KY; Shelton DK; Beckett LA; Gandara DR
    J Thorac Oncol; 2007 Jun; 2(6):537-43. PubMed ID: 17545850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical diffuse bilateral cystic lung changes secondary to erlotinib treatment in a patient with metastatic non-small cell lung carcinoma: A case report and literature review.
    Ansari J; Batubara E; Ali M; Farrag A; Bashir F; Farghaly HR; Ali AM; Shaukat A
    Mol Clin Oncol; 2018 Jul; 9(1):92-95. PubMed ID: 29977544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation recall pneumonitis induced by erlotinib after palliative thoracic radiotherapy for lung cancer: Case report and literature review.
    Awad R; Nott L
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):91-5. PubMed ID: 26846159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature.
    ter Heine R; van den Bosch RT; Schaefer-Prokop CM; Lankheet NA; Beijnen JH; Staaks GH; van der Westerlaken MM; Malingré MM; van den Brand JJ
    Lung Cancer; 2012 Mar; 75(3):391-7. PubMed ID: 22101147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis.
    Um SJ; Lee SK; Yang DK; Son C; Roh MS; Kim KN; Lee KN; Choi PJ
    Clin Respir J; 2009 Jul; 3(3):181-4. PubMed ID: 20298401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatal asymmetric interstitial lung disease after erlotinib for lung cancer.
    Ren S; Li Y; Li W; Zhao Z; Jin C; Zhang D
    Respiration; 2012; 84(5):431-5. PubMed ID: 22889962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Afatinib-Induced Acute Fatal Pneumonitis in Metastatic Lung Adenocarcinoma.
    Yoo SH; Ryu JA; Kim SR; Oh SY; Jung GS; Lee DJ; Kwak BG; Nam YH; Kim KH; Yang YJ
    Korean J Fam Med; 2016 Nov; 37(6):351-355. PubMed ID: 27900074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erlotinib-associated interstitial lung disease in advanced pancreatic carcinoma: a case report and literature review.
    Macerelli M; Mazzer M; Foltran L; Cardellino GG; Aprile G
    Tumori; 2015 Jul; 101(4):e122-7. PubMed ID: 25953445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
    Smith J
    Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.
    Shi L; Tang J; Tong L; Liu Z
    Lung Cancer; 2014 Feb; 83(2):231-9. PubMed ID: 24332320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib--a cohort study.
    Johkoh T; Sakai F; Kusumoto M; Arakawa H; Harada R; Ueda M; Kudoh S; Fukuoka M
    Clin Lung Cancer; 2014 Nov; 15(6):448-54. PubMed ID: 25043209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatal interstitial lung disease after addition of sorafenib to a patient with lung adenocarcinoma who had failed to improve with erlotinib alone.
    Guan Y; Meng J; Zhao H; Hu Y; Yan X; Zhao SH; Jiao SC
    Case Rep Oncol; 2014 Jan; 7(1):273-6. PubMed ID: 24926256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.